The Medical Letter on Drugs and Therapeutics
Buprenorphine Buccal Film (Belbuca) for Chronic Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Belbuca (Endo), a buccal formulation of the partial opioid agonist buprenorphine, has been approved by the FDA for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Buprenorphine is also available as a transdermal patch (Butrans) and in a parenteral formulation (Buprenex, and generics) for treatment of pain. A sublingual formulation of buprenorphine and buccal and sublingual formulations containing buprenorphine and the opioid antagonist naloxone are approved for use as alternatives to methadone for treatment of opioid dependence.1,2

MECHANISM OF ACTION — Buprenorphine binds with high affinity to, and slowly dissociates from, the mu-opioid receptor. In the dosage range for which Belbuca is approved, buprenorphine produces typical opioid agonist effects. In higher doses, its agonist effects reach ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Buprenorphine Buccal Film (Belbuca) for Chronic Pain
Article code: 1492b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian